Zealand Pharma Initiates Phase 2 ZYNERGY Trial of Petrelintide and Enicepatide Combination for Obesity

Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming metabolic health so millions can live without limits, announces ...

November 19, 2026 | Thursday | News
Erasca and Bristol Myers Squibb Partner to Test ERAS-0015 Combination in Pancreatic Cancer

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p...

November 19, 2026 | Thursday | News
Labcorp Partners with Grupo Fleury to Expand Clinical Trial Laboratory Operations in Brazil

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced a collaboration with Grupo Fleury, one of Brazil's ...

November 19, 2026 | Thursday | News
Cancer Research UK and Dewpoint Therapeutics Partner to Advance MYC-Targeting Cancer Drug into Phase 1/2a Trial

DPTX8743 is a potential first-in-class small molecule modulator of MYC condensates, targeting one of cancer’s most important and historically undrugg...

November 18, 2026 | Wednesday | News
AriBio Reports Mixed Phase 3 Results for Oral AR1001 in Early Alzheimer’s Disease

AR1001 met the primary endpoint in the prespecified Monotherapy population, with a CDR-SB treatment difference of -0.44 points versus placebo at Week 52 (p...

November 18, 2026 | Wednesday | News
Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib for Moderate-to-Severe Lichen Planus

Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed I...

November 17, 2026 | Tuesday | News
Novo Nordisk Seeks FDA and EMA Approval for Etavopivat to Treat Sickle Cell Disease

  The FDA New Drug Application (NDA) and EMA Marketing Authorization Application (MAA) submissions for etavopivat are based on da...

November 16, 2026 | Monday | News
Regeneron Reports Positive Phase 2 Results for Baloncibart in POTS, Plans Phase 3 Trial in 2027

POTS (postural orthostatic tachycardia syndrome) is a debilitating condition characterized by a marked increase in heart rate upon standing and associated ...

November 16, 2026 | Monday | News
Eisai and Biogen Launch LEQEMBI Pen in Japan for Once-Weekly Alzheimer's Disease Treatment

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced that “LEQEMBI® Pen”, the subcutaneous (SC) formulation of “LEQEMBI®&rdqu...

November 16, 2026 | Monday | News
NanoImaging Services and Proteos Launch TrueCourse Biosciences to Integrate Drug Discovery Capabilities

NanoImaging Services, a cryo-EM CRO, and Proteos, a protein production research partner, have  announced the launch of TrueCourse Biosciences, an in...

September 24, 2026 | Thursday | News
Designing the Next Generation of Cell and Gene Therapies for Scale

  As cell and gene therapies progress towards broader commercialisation, scientific innovation alone is no longer enough. The next generation of ther...

September 17, 2026 | Thursday | Interaction
Lonza Expands US Spray-Drying Capacity with New Commercial Facility in Oregon

  Lonza will build a new large-scale, commercial PSD-4 spray-drying facility in Bend, Oregon (US) to support a rapidly expanding market segment ...

September 11, 2026 | Friday | News
Quotient Sciences on How AI Is Reshaping the CDMO–Sponsor Relationship

    As AI and digital technologies increasingly influence pharmaceutical development, CDMOs are taking on a broader role in helping sponsors im...

August 25, 2026 | Tuesday | Interaction
PacBio Boosts Vega HiFi Sequencing Output by 50% with New SPRQ-Nx Chemistry

PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, announced the upcoming availability of SPRQ-Nx chemistry and...

August 13, 2026 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close